Study of a new drug for advanced lung cancer and solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, XTX501, for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if the drug can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have measurable tumors that can be seen on scans
- You are well enough to be up and about (ECOG score 0 or 1)
- Your organs (like liver, kidneys) are working well enough
- You have metastatic non-small cell lung cancer and your tumor has been tested for certain gene changes (EGFR, ALK, ROS1, RET, MET, HER-2, NTRK) - you cannot have these changes
- You have gotten benefit from a prior immunotherapy drug (PD-1 or PD-L1 inhibitor) for at least 6 months without your cancer growing
- You have not had treatment with IL-2 before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.